Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis


Autoria(s): Barichello, Tatiana; Ceretta, Renan A.; Generoso, Jaqueline S.; Moreira, Ana Paula; Simoes, Lutiana R.; Comim, Clarissa M.; Quevedo, Joao; Vilela, Marcia Carvalho; Zuardi, Antonio Waldo; Crippa, José A.; Teixeira, Antonio Lucio
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

Pneumococcal meningitis is a life-threatening disease characterized by an acute infection affecting the pia matter, arachnoid and subarachnoid space. The intense inflammatory response is associated with a significant mortality rate and neurologic sequelae, such as, seizures, sensory-motor deficits and impairment of learning and memory. The aim of this study was to evaluate the effects of acute and extended administration of cannabidiol on pro-inflammatory cytokines and behavioral parameters in adult Wistar rats submitted to pneumococcal meningitis. Male Wistar rats underwent a cisterna magna tap and received either 10 mu l of sterile saline as a placebo or an equivalent volume of S. pneumoniae suspension. Rats subjected to meningitis were treated by intraperitoneal injection with cannabidiol (2.5, 5, or 10 mg/kg once or daily for 9 days after meningitis induction) or a placebo. Six hours after meningitis induction, the rats that received one dose were killed and the hippocampus and frontal cortex were obtained to assess cytokines/chemokine and brain-derived neurotrophic factor levels. On the 10th day, the rats were submitted to the inhibitory avoidance task. After the task, the animals were killed and samples from the hippocampus and frontal cortex were obtained. The extended administration of cannabidiol at different doses reduced the TNF-alpha level in frontal cortex. Prolonged treatment with canabidiol, 10 mg/kg, prevented memory impairment in rats with pneumococcal meningitis. Although descriptive, our results demonstrate that cannabidiol has anti-inflammatory effects in pneumococcal meningitis and prevents cognitive sequel. (C) 2012 Elsevier B.V. All rights reserved.

CNPq

FAPEMIG

FAPESC

UNESC

NENASC project (PRONEX program CNPq/FAPESC)

INCT-TM

Research Support Center on Applied Neuroscience (NAPNA-USP) [2011.1.9333.1.3]

L'Oreal-UNESCO Brazil Fellowship for Women in Science

Identificador

EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, v. 697, n. 41334, supl. 1, Part 6, pp. 158-164, DEC 15, 2012

0014-2999

http://www.producao.usp.br/handle/BDPI/42261

10.1016/j.ejphar.2012.09.053

http://dx.doi.org/10.1016/j.ejphar.2012.09.053

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

AMSTERDAM

Relação

EUROPEAN JOURNAL OF PHARMACOLOGY

Direitos

closedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #STREPTOCOCCUS PNEUMONIAE #MENINGITIS #CYTOKINE #CHEMOKINE #MEMORY #CANNABIDIOL #BLOOD-BRAIN-BARRIER #KAPPA-B ACTIVATION #BACTERIAL-MENINGITIS #OXIDATIVE STRESS #STREPTOCOCCUS-PNEUMONIAE #CEREBROSPINAL-FLUID #PROTECTIVE ROLE #TNF-ALPHA #INFLAMMATION #INJURY #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion